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Introduction
Testicular germ cell tumor (TGCT) is a prototypic can-
cer of young adults. It can be highly malignant, but is
also highly curable (approximately 80%), even at an ad-
vanced stage, with modern therapy. TGCT is rare in
the Asian population, but is the most common malig-
nancy in adolescent and young adult males aged 15–
35 years in Western countries. The age-standardized
incidence rate worldwide is approximately 1.5/100,000
with substantial variations between countries.1 It is
more common in Caucasians and its incidence has
increased.2 TGCTs are rare in African and Asian pop-
ulations, even after migration.3 Only a few cases have
been reported in Taiwan.4 It has been emphasized that
it should be managed by an experienced team. We dis-
cuss the experience of TGCTs in the USA and Taiwan
and present a case with current evidence-based medi-
cine (EBM) illustration (Table 1). We also discuss how
to treat this potentially curable disease.
Case Illustration
A 17-year-old male student visited the genitourinary
clinic in early June 2008 due to the new onset of painful
swelling of the left scrotum. He was treated with dif-
ferent antibiotics without a response with suspected
left epididymitis. The patient had lost 20 kg (89 kg
down to 69 kg) in 6 months. Physically, he had swollen
left scrotal content with tenderness and local heat
without palpable inguinal lymph nodes. Laboratory
tests showed negative urinalysis, but there was leuko-
cytosis (12,070/μL). Computed tomography (CT)
of the abdomen and pelvis performed on August 22,
2008 showed an enhanced left testicular mass (2.3 cm)
with heterogeneous density, multiple left para-aortic
and inguinal lymph nodes (the largest was 2 cm), and
multiple hepatic tumors in both lobes (the largest was
9 cm) (Figure 1A). Further laboratory tests revealed
mild elevation of serum aspartate aminotransferase
levels (37 IU/L) and substantial elevations of lactic
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dehydrogenase (LDH) (2,189 IU/L), β-human cho-
rionic gonadotropin (HCG) (26.5 mIU/mL), and 
α-fetoprotein (AFP) (371 ng/mL) levels (Table 2).
Based on the CT findings, left orchiectomy with left
inguinal lymph node dissection was performed on
August 25, 2008. Pathology showed embryonal car-
cinoma of the left testis and negative inguinal lymph
node involvement.
Medical oncologists started to be involved in the
patient’s care from August 28, 2008. After reviewing
the pathology, we discussed in detail the prognosis,
goals of treatment and preparations before chemother-
apy with the patient and his family.
Preparation
The patient’s family had requested 2nd and 3rd opinions
from 2 other major tertiary medical centers, and both
gave advice similar to ours. Therefore, they decided
to stay at our hospital for treatment. We gave them 
a detailed treatment plan. The patient had a port-A
catheter inserted by a general surgeon for future
chemotherapy. He also had a pulmonary function test,
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Table 1. Different levels of evidence-based medicine applied in
this article (from the Oxford Centre for Evidence Based Medicine
Levels of Evidence, March 2009)*
Level Therapy/prevention, etiology/harm
1a SR (with homogeneity) of RCTs
1b Individual RCT (with narrow confidence interval)
1c All or none
2a SR (with homogeneity) of cohort studies
2b Individual cohort study (including low quality RCT; 
e.g. < 80% follow-up)
2c “Outcomes” research; ecological studies
3a SR (with homogeneity) of case-control studies
3b Individual case-control study
4 Case-series (and poor quality cohort and 
case-control studies)
5 Expert opinion without explicit critical appraisal, or 
based on physiology, bench research or “first 
principles”
*Produced by Bob Phillips, Chris Ball, Dave Sackett, Doug Badenoch, Sharon
Straus, Brian Haynes, Martin Dawes since November 1998 and updated by
Jeremy Howick in March 2009; freely available from the Oxford Centre for
Evidence Based Medicine website (http://www.cebm.net/). SR = systematic
review; RCT = randomized controlled trial.
Table 2. Serial tumor markers of the case illustration
Date
HCG (mIU/mL) AFP (ng/mL) LDH (IU/L)
(0–5) (0–10) (95–215)
8–25/08 27 371 2,189
9–10/08 – – 4,805
9–18/08 279 1,752 3,175
9–22/08 159 961 1,073
9–26/08 – – 662
10–2/08 – – 448
10–11/08 – – 197
10–20/08 < 1 14 374
10–26/08 – 6.4 219
11–13/08 < 1 3.7 231
2–4/09 < 1 2.8 256
3–2/09 < 1 2.8 207
4–8/09 < 1 3.3 –
5–13/09 < 1 2.6 209
6–17/09 < 1 2.9 –
7–27/09 < 1 2.5 –
9–4/09 < 1 2.1 –
10–21/09 < 1 2.9 206
12–16/09 < 1 2.5 203
1–27/10 < 1 2.8 –
3–19/10 < 1 3.4 –
5–5/10 < 1 2.4 207
HCG = b-human chorionic gonadotropin; AFP =a-fetoprotein; LDH = lactate
dehydrogenase.
BA
Figure 1. Computed tomography (CT) of the abdomen before and after treatment taken at the same level. (A) Initial CT taken on August
22, 2008 shows multiple liver metastases. (B) Recent CT taken on March 12, 2010 shows improvement.
which revealed normal results before bleomycin treat-
ment.5 He also had sperm preservation before starting
chemotherapy (EBM level 3b).6
Staging
The patient’s pathology was embryonal carcinoma, one
of the nonseminomatous germ cell tumors (NSGCTs)
without a teratoma element. During the preparation
period, he developed severe lower back pain without
evidence of spinal cord compression by neurosurgical
evaluation. A bone scan was negative for bone metas-
tasis. He required constant narcotic medication. We be-
lieve that this was due to progressive retroperitoneal
lymph node enlargement (because his pain subsided
after the 1st chemotherapy). His liver was also enlarged,
with tenderness on examination. LDH levels were ele-
vated to 4,805 IU/L before the beginning of treat-
ment. In addition, bilateral pulmonary metastases were
shown on a CT scan, as well as liver metastases as men-
tioned above. Therefore, the patient was diagnosed as
stage IIIC (T2N1M1bS3) (Table 3)7 and in the poor-
risk group (Table 4).8
Treatment
We decided to give the patient 4 cycles of bleomycin
30 mg weekly, etoposide 100 mg/m2 daily × 5 and
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Table 3. American Joint Committee on Cancer Clinical staging for testicular germ cell tumors7
Tumor (pathological)
T1 Limited to testis/epididymis without lymphovascular invasion. May invade tunica albuginea but not 
tunica vaginalis.
T2 Limited to testis/epididymis with lymphovascular invasion or extending to involve tunica vaginalis.
T3 Invades spermatic cord with or without vascular/lymphatic invasion.
T4 Invades scrotum with or without vascular/lymphatic invasion.
Node
N0 No regional lymph node metastasis.
N1 Lymph node mass ≤ 2 cm in greatest dimension or multiple lymph nodes, none > 2 cm in 
greatest dimension.
N2 Lymph node mass > 2 cm but not > 5 cm in greatest dimension, or multiple lymph nodes,
any 1 mass > 2 cm but not > 5 cm in greatest dimension.
N3 Lymph node mass > 5 cm in greatest dimension.
Metastasis
M0 No distant metastasis.
M1a Nonregional lymph node or pulmonary metastasis.
M1b Distant metastasis other than to nonregional lymph nodes and lungs.
Tumor markers (serum)
S0 Markers within normal limits.
S1 LDH < 1.5 × N & HCG < 5,000 & AFP < 1,000.
S2 LDH > 1.5–10 N or HCG 5,000–50,000 or AFP 1,000–10,000.
S3 LDH > 10 × N or HCG > 50,000 or AFP > 10,000.
Stage Extent of disease
Grouping
I Confined to the testis (any T, N0, M0).
IA pT1, N0, M0, S0.
IB pT2 or pT3 or pT4, N0, M0, S0.
IS Any T, N0, M0, S1–3.
II Metastatic disease to the nodes of the periaortic or vena caval zone without pulmonary or visceral 
involvement (any T, any N 1–3, M0).
IIA Any T, N1, M0, S0–1.
IIB Any T, N2, M0, S0–1.
IIC Any T, N3, M0, S0–1.
III Metastasis above the diaphragm or involving other viscera or S2–3.
IIIA Any T, any N, M1a, S0–1.
IIIB Any T, N1–3, M0–1a, S2.
IIIC Any T, N1–3, M0, S3; or any T, any N, M1a, S3; or any T, any N, M1b, any S.
N = upper limit of normal for the LDH assay; LDH = lactate dehydrogenase (IU/L); HCG = b-human chorionic gonadotropin (mIU/mL); AFP =a-fetoprotein (ng/mL).
cisplatin 20 mg/m2 daily × 5 (BEP) due to high-risk
stage IIIC (EBM levels 1b10,12–14 and 2b11).9–14 The
chemotherapy began on September 11, 2008 and fin-
ished on November 28, 2008, and the patient
responded well. He received the full doses on a set
schedule9 with supplement of granulocyte-colony stim-
ulating factor (G-CSF) in all cycles (EBM level 2a).15
His absolute neutrophil count dropped to 288/μL on
day 12 after the 1st cycle of chemotherapy was compli-
cated with acute tonsillitis. All tumor markers returned
to normal before the 3rd cycle of chemotherapy (Table
2; EBM levels 2b17 and 3b16).16,17 Follow-up CT of
the chest on October 22, 2008 revealed total disappear-
ance of the pulmonary metastases. The patient’s retro-
peritoneal lymph nodes also regressed in December
2008, but his liver lesions remained in both lobes, with
the largest being 2.4 cm. We decided that he could
not have post-chemotherapy resection due to multi-
ple lesions in both lobes of the liver (EBM levels 2b,20
3a,21 and 3b18,19,22).18–22 Instead, he underwent CT-
guided biopsy of the largest liver lesion, which showed
marked tumor necrosis with focal fibrosis.
Problems, intervention, and outcome
The main problem of the presented case was stage IIIC
NSGCT belonging to the high-risk group.7,8 There
are many different chemotherapy regimens for TGCT.
Based on the above evidence-based literature, our
patient received BEP × 4 of the original 5-day regimen
(EBM levels 1b10,12–14,23 and 2b11),9–14,23 without com-
promising the dose or delaying the schedule. This is
the standard treatment for high-risk NSGCT in stage
IIIC. He had an excellent response and is still in com-
plete remission according to the latest physical exami-
nation, tumor markers (EBM levels 2b17 and 3b16)16,17
(Table 2) and imaging studies (Figure 1B). Another
problem was severe neutropenia with acute tonsillitis
after the 1st cycle of chemotherapy. This was a compli-
cation from the treatment. In general, prophylactic
G-CSF is not indicated. In this case, because of the
infection with severe neutropenia, the patient received
G-CSF in each cycle. He was able to keep his chemo-
therapy schedule on time and without compromising
the dose (EBM level 2a15).9,15 There were no further
infectious complications. This was considered to be a
successful key point. However, we needed to decide
whether the patient should have laparotomy to resect
the residual masses shown on CT after 4 cycles of
BEP. This is a controversial issue (EBM levels 2b,20
3a21 and 3b18,19,22).18–22,24 His retroperitoneal lymph
nodes were nearly gone (< 1 cm) and pulmonary
lesions had completely disappeared. The lesions were
present in both lobes of the liver, which could not be
resected completely unless there was an intention to
have a liver transplant. The patient had no teratoma
elements in the initial pathology, which made the pos-
sibility of teratoma of these residual masses less likely.
Therefore, he had CT-guided biopsy to the largest
liver lesion instead of laparotomy resection. Other ma-
jor symptoms and signs were weight loss, severe pain,
hepatomegaly and marked elevation of tumor markers.
These all resolved after treatment.
Follow-up
The serial follow-up of tumor markers was normal
(Table 2). In July 2009, a thymic tumor was suspected
from CT of the chest. Video-assisted thoracic surgical
resection of the thymus was performed, and the pa-
thology revealed only thymic hyperplasia without evi-
dence of tumor recurrence. CT of the chest, abdomen
(Figure 1B) and pelvis revealed no evidence of active
disease. The patient is currently in complete remission
as shown by normal tumor markers, even though there
were residual liver lesions shown on CT that were
necrotic, and fibrotic tissue on biopsy. Continued 
follow-up for relapse and late relapse25,26 are needed
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Table 4. Germ cell tumor risk classification8
Classification Seminoma Nonseminoma
Good risk Any HCG AFP < 1,000
Any LDH HCG < 5,000
LDH < 1.5 × ULN
Nonpulmonary Nonpulmonary visceral
visceral
Metastasis absent Metastases absent
Any primary site Gonadal or 
retroperitoneal primary 
tumor
Intermediate Any HCG AFP 1,000–10,000
risk Any LDH HCG 5,000–50,000
LDH 1.5–10.0 × ULN
Nonpulmonary Nonpulmonary visceral
visceral
Metastasis present Metastases absent
Any primary site Gonadal or 
retroperitoneal primary 
site
Poor risk Not applicable AFP ≥ 10,000
HCG ≥ 50,000
LDH ≥ 10 × ULN
Mediastinal primary 
site
Nonpulmonary visceral 
metastases present 
(e.g. bone, liver, brain)
HCG = b-human chorionic gonadotropin (mIU/mL); AFP =a-fetoprotein
(ng/mL); LDH = lactate dehydrogenase (IU/L); ULN = upper limit of normal.
(EBM level 3b). Long-term complications related to
the BEP regimen are also future possibilities (EBM
levels 3a27 and 3b28–30).5,27–30
Biology, Pathology and Staging
Biology
Recent gene expression profiling studies of TGCTs
along with advances in embryonic stem-cell research
have contributed to understanding the biology of the
disease. Gain of the short arm of chromosome 12
detected in almost all adult germ cell tumors (GCTs)
appears to be malfunctional in germ cell tumorigene-
sis, based on the observed overexpression of genes
mapped to this region involved in maintaining pluripo-
tency and oncogenesis.31
Pathology
GCTs are classified into 2 broad histological categories:
seminomatous and nonseminomatous GCT. Patients
with seminoma who have increased AFP levels or any
of the NSGCT components (including teratoma) are
considered to have a NSGCT. NSGCT is further di-
vided into 4 types as follows.1 (1) Embryonal carci-
noma is composed of large pleomorphic cells with
different architectural patterns. It is the most undif-
ferentiated cell type. This tumor may be associated
with an elevation of HCG and/or AFP serum levels,
as in our case. (2) Endodermal sinus tumor (yolk sac
carcinoma) is the most common testicular tumor seen
in infants and young children. It is uncommon in the
adult testis but accounts for a significant percentage of
primary mediastinal NSGCT. It has a variety of archi-
tectural patterns. Yolk sac tumor mimics the yolk sac
of the embryo, producing AFP. (3) Choriocarcinoma,
as a pure entity, is one of the least common GCTs.
These tumors have a great propensity for hematoge-
nous spread, often skipping the retroperitoneum. It is
associated with an elevated serum level of HCG. (4)
Teratoma is generally a benign tumor with elements
from 2 or more of the germ layers (ectoderm, meso-
derm, and the endoderm). Teratoma is uncommonly
seen as the sole histology in primary tumors, but it is
frequently associated with other histological elements
mentioned above. Serum markers are normal in patients
with pure teratoma.
Prognostic classification
GCTs are spread by both lymphatic and vascular chan-
nels. Prognosis is related not only to the anatomic ex-
tent of the spread but also to the primary site and the
extent of production of the tumor markers (EBM
level 3b).32 These features incorporate several prognos-
tic factor classifications of widely differing types and
complexity, and it is difficult to compare between dif-
ferent classifications (EBM level 3b).33 As a result, the
International Germ Cell Cancer Collaborative Group
(IGCCCG) was formed in 1991. Members agreed
to pool clinical data on a large population of patients
with metastatic GCT. An agreed prognostic factor
classification for use in clinical practice and future trials
has resulted from this collaboration. A consensus clas-
sification was defined (poor, intermediate, and good)
and published in 1997 (Table 4).8 The American
Joint Committee on Cancer adopted this classification
in its staging manual beginning from the 6th edition
(Table 3).7
Clinical Management
Treatment of patients with advanced disease
IGCCCG classification is the only risk assignment
algorithm used today in clinical trials and clinical prac-
tice. Patients are categorized as good, intermediate,
or poor risk and the projected 5-year survival rates are
approximately 90%, 75%, and 45%, respectively.8
Good-risk GCT
After trials in the late 1970s and early 1980s, the cur-
ability of metastatic GCT was established. Strategies
were then necessary to decrease the toxicity resulting
from therapy. Elimination of bleomycin, substitution
of carboplatin for cisplatin, and a reduced number of
chemotherapy cycles were studied systematically (EBM
level 1b).34–36 The results of phase 3 randomized tri-
als showed that carboplatin was inferior to cisplatin 
in combination with etoposide (EBM level 1b).36,37
In contrast, bleomycin could be eliminated from ther-
apy when 4 cycles of etoposide plus cisplatin had been
administered (EBM level 1b).38 Bleomycin toxicity
remains an important issue in good-risk patients.5
Acute pulmonary toxicity is reduced with BEP × 3
(EBM level 3b39).5,39 Moreover, long-term cardiovas-
cular diseases are now recognized in connection with
BEP therapy (EBM level 3b).28,40 Raynaud’s phenom-
enon is reported to occur in 6–24% of patients (EBM
level 1b).35 Therefore, a randomized trial comparing
BEP × 3 with EP × 4 was designed. It was concluded
that the regimen of EP × 4 is an alternative to BEP × 3
in good-risk GCT (EBM levels 1b41 and 3a42).41,42 In
addition, the drug dose was determined to be crucial,
as survival was superior with an etoposide 500 mg/
m2/cycle compared with a 360 mg/m2/cycle (EBM
level 1b).38
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Poor- and intermediate-risk GCT
Of patients with metastatic disease, 20–30% appear to
be more resistant to initial treatment. Hoping for a
better response, double-dose cisplatin and other dose-
escalation regimens, as well as alternating and se-
quential regimens, have been tried, but they did not
improve on the standard BEP × 4 (EBM levels 1b13,14
and 2b11).11,13,14 In a randomized trial comparing
BEP × 4 versus VP-16 plus ifosfamide plus platinum
(VIP) × 4, the response rates and survival were com-
parable, but VIP had more hematological toxicity
(EBM level 1b).10 VIP can be offered as an alternative
therapy for patients with compromised pulmonary
function or other pre-existing conditions precluding
treatment with the standard BEP regimen (EBM level
1b).12 Another randomized trial compared BEP × 4
with BEP × 2 followed by high-dose therapy (carbo-
platin, etoposide and cyclophosphamide with autolo-
gous stem-cell rescue) and showed no difference in
outcome (EBM level 1b).23 Chemotherapy should be
given without dose reduction at 21-day intervals. Dose
reduction is highly discouraged, even in the setting of
a critically-ill patient.9 Postponing treatment (a maxi-
mum of 3 days for each decision) should rarely be
considered. For example, in cases of existing fever,
with a neutrophil count < 500/μL or platelet counts
< 10,000/μL at day 1 of a subsequent cycle,9 there is
no indication for routine prophylactic use of hemato-
poietic growth factors such as G-CSF (EBM level 2a).43
However, if serious infections have occurred during 
1 preceding chemotherapy cycle, as in the presented
case, prophylactic application of G-CSF is recom-
mended in subsequent cycles to maintain the required
dose intensity (EBM level 2a).15 The original 5-day
BEP regimen for 4 cycles is standard in intermediate-
and poor-risk GCT.9
Approximately 10% of all patients with advanced
GCT (i.e. 1–2% of all GCTs) present with brain metas-
tases. These patients have a long-term survival of 30–
40%, whereas patients who develop brain metastases
with other metastases during first-line therapy have a
5-year survival rate of only 2–5% (EBM level 3b).44
Monitoring treatment results
Tumor markers and imaging studies are the 2 major
tests to monitor the treatment results of GCT (EBM
level 2a).45 The frequency and type of examinations
depend on the estimated risk of relapse, the chosen
treatment strategy, and the time elapsed since the com-
pletion of treatment and should be modified accord-
ing to their risks. It is important that the markers be
measured directly before each treatment cycle, other-
wise, the markers can be falsely increased due to release
from necrotic tumor cells.9 A tumor marker (HCG,
AFP, and LDH) surge was noted in the very first few
weeks after initiation of chemotherapy (EBM level
2b).17 After the transient elevation, the rate of decline
of HCG (half-life, 18–36 hours) and AFP (half-life,
5–7 days) has a prognostic impact on both progression-
free survival and overall survival, especially in patients
with a poor prognosis, as seen in this case (EBM level
3b16).16,46 After normalization of these markers, they
should be followed more frequently at the beginning
of treatment and less often later on. The same princi-
ple applies to imaging studies. In patients with a slow
marker decline or clinical evidence of progression, radio-
logical restaging should be considered (EBM level
3b).47 The images should include CT of the abdomen
and pelvis with contrast and other organs of initial
involvement. Positron emission tomography scans are
very useful in seminoma patients for residual disease
evaluation (EBM level 2b).48 However, they are not
sensitive enough for NSGCT (EBM levels 2b49 and
3b50).49,50 Progression with tumor markers despite first-
line chemotherapy requires the immediate initiation of
salvage treatment (EBM levels 2b17 and 3b51).17,51
Resection of residual masses should be performed in
patients with tumor markers persisting at low levels after
completion of first-line treatment (EBM level 2b).52
Resection of residual tumor
Seminoma
In patients with seminoma, residual masses present
after chemotherapy and after radiotherapy should not
be resected, but should be closely followed by tumor
marker determinations and imaging studies (EBM level
4).53 Fluorodeoxyglucose-positron emission tomog-
raphy has a prognostic value in this situation, especially
with residual lesions > 3 cm. If the result is negative,
no resection or any other treatment is necessary. If
the result is positive, histology should be obtained by
biopsy or preferably by resection (EBM level 2b).48
Further treatment should be based on the results of
histology and may include observation, radiation, or
further chemotherapy (EBM level 3b).54
Nonseminoma
Patients with nonseminoma who achieve serologic
complete remission (normalization of all tumor mark-
ers) will have either complete regression of radiographic
abnormalities or persistent radiographic masses. No
post-chemotherapy surgery is required in the former
situation; there is significant controversy with regard
to the latter situation (EBM level 3b).19 Patients who
are initially teratoma-negative and who have more than
90% radiological regression can be followed closely
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without resection. However, surgical resection is an-
other option (EBM level 3b).22 In all other situations,
all residual masses should be resected if technically
feasible (EBM level 3b18).18,24 Histology of residual
masses after first-line chemotherapy shows necrosis
(50%), mature teratoma (35%), and vital cancer (15%)
(EBM levels 2b20 and 3a21).20,21 Complete resection
of residual teratomas is important because it may prog-
ress to obstruct or invade adjacent structures, and is
associated with a malignant transformation risk and
higher rate of late relapse.24
Consolidation chemotherapy after secondary
surgery
If the resection histology shows necrosis or teratoma,
no further treatment is required. When a viable undif-
ferentiated tumor is found from resection, the role of
consolidation chemotherapy is uncertain (EBM level
3b).18 If > 10% of viable cancer is found, or if com-
pleteness of the resection is in doubt, consolidation
chemotherapy might be justified.
Salvage chemotherapy for relapsed or refractory
disease
In patients who relapse or progress after first-line
chemotherapy, prognostic indicators are the localization
and histology of the primary tumor, response to first-
line treatment, duration of previous remissions, and the
levels of tumor markers (EBM level 2b).55 Caution
should be used when suspicion of relapse is based on
elevations in tumor markers only. Elevation of AFP
can occur from lab errors, hepatoma or liver inflam-
mation. False elevation of HCG may occur in patients
who use marijuana, and there is some cross-reactivity
in the radioimmunoassay with luteinizing hormone.56
The common regimens in second- or third-line che-
motherapy are paclitaxel plus ifosfamide plus cisplatin
(TIP),57 VIP,10 vinblastin plus ifosfamide plus cisplatin
(VeIP)58,59 or high-dose chemotherapy.60,61
Late relapse
A late relapse is defined as any disease recurrence more
than 2 years after completing first-line treatment, and
was not recognized before 1983. A pooled analysis of
a large series published between 1989 and 2006 showed
a crude incidence of 3.2% for nonseminoma and 1.4%
for seminoma (EBM levels 3a25 and 3b26).25,26,62 The
most important observation on late relapse in patients
who have received cisplatin-based combination chemo-
therapy is that surgical resection of all recurrent disease
is important in determining outcome. This is due to rel-
ative resistance to chemotherapy, but is also due to the
frequency of teratoma within the recurrence (EBM
levels 3a25 and 3b26).25,26,62 If the lesions are not com-
pletely resectable, biopsies should be obtained for his-
tological assessment and salvage chemotherapy should
be initiated according to the histological results.
Follow-up, late effects, and psychosocial impact
The aims of follow-up of patients with GCT are detec-
tion of relapse, diagnosis of second cancers and their
prevention, and treatment of physical and psychologi-
cal modalities related to GCT or its treatment. Given
the long life expectancy of this young patient popula-
tion, evaluating long-term complications has become
increasingly important. First, the risk of a second ma-
lignancy has increased; contralateral testicular cancer
is highest, between 2–5%, during the first 15 years
(EBM level 3b).63 Other second malignancies are car-
cinomas in prior radiation fields, and myelodysplasia
or leukemia are often associated with etoposide dose
(EBM level 3a).27,64 Cases of leukemia after cumula-
tive doses of etoposide < 2 g have a reported inci-
dence of 0.6%, and incidence is 2% if etoposide dose is
≥ 2 g (EBM level 3a)64 (our patient received a total of
3,175 mg).
Second, there is the issue of medical late toxicity of
chemotherapy. Cisplatin can cause renal dysfunction
with a decreasing glomerular filtration rate (EBM level
3b)65 and high-frequency hearing loss in 20–40% of
patients (EBM level 3b).66 Gonadal dysfunction is com-
mon in patients treated with orchiectomy only. Bleo-
mycin can cause pulmonary fibrosis (approximately 5%;
EBM level 3b67)5,67 and Raynaud’s phenomenon (EBM
level 3b).68 The risks of cardiovascular disease (EBM
level 3b)28 and metabolic syndrome (EBM level 3b)29
are also increased and should be actively monitored.
Third, there are late psychosocial effects among
GCT survivors. These include fear of recurrence, sur-
vivor guilt, sleep disturbance, cognitive dysfunction,
anxiety or depression, difficulty forming relationships,
and sexual dysfunction (EBM level 3b).30,69
Conclusion
We have presented a case with far-advanced embry-
onal carcinoma (stage IIIC) treated with current evi-
dence-based therapy that has had very good results.
Survival rates with modern therapy in GCT are high.
EP × 4 or BEP × 3 is standard therapy for patients with
good-risk features, and the cure rate is approximately
90%. Post-chemotherapy resection of all residual
masses shown on imaging studies is advised if techni-
cally feasible, but there are some controversial issues.
BEP × 4 is the standard therapy for intermediate- or
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poor-prognosis groups. Approximately 75% of patients
in the intermediate-risk group and 45% of patients in
the poor-risk group achieve a durable complete remis-
sion with these therapies. Patients requiring second-
or third-line treatment are managed with TIP, VIP,
VeIP, high-dose chemotherapy regimens, or a clinical
trial. Finally, with the high rate of survival, quality care
must include attention to the long-term outcomes of
these young adult patients.
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